Alexion announced financial results for the year 2018 … more

Alexion plans to hold an Investor Day on March 20, at which it will highlight its rare disease portfolio … more

Alexion and Caelum Biosciences report a collaboration to develop CAEL-101 for light chain amyloidosis. CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis … more

Alexion announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its primary objective in complement inhibitor-naïve patients with atypical hemolytic uremic syndrome … more

Read the New Haven Register article on ULTOMIRIS™ here.